AUTHORS
Lin Xu, PhD, Yi Zheng2, Yaping Wang3, Lin Zhao4, Yunqing Xu5, Guijiang Wang6, Yuanhua Cai, MD, PhD7, Hu Zhou8, Zhixiang Chen, MD9, Xiaofan Li Sr, MD, PhD10, Shaoyuan Wang11
AFFILIATIONS
1 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
2 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
3 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
4 School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian, China
5 School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian, China
6 School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian, China
7 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
8 School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian, China
9 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
10 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
11 Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
ABSTRACT
Venetoclax-based regimens constitute the standard frontline therapy for acute myeloid leukemia (AML), yet MCL1 overexpression is a major driver of acquired resistance, limiting durable clinical remission. Ras-GAP SH3 domain-binding proteins (G3BP1/2), core components of stress granules (SGs), are tightly associated with poor prognosis and chemoresistance in multiple malignancies. Our previous work validated that G3BP2 depletion sensitizes AML cells to venetoclax treatment. However, no clinically applicable G3BP inhibitors are available to date. Herein, we aimed to identify repurposed FDA-approved agents targeting G3BP1/2 and evaluate their synergistic anti-leukemic efficacy with venetoclax in AML.
We performed structure-based virtual screening focused on the conserved NTF2-like (NTF2L) pocket of G3BP1 and G3BP2 using a library of FDA-approved compounds. Momelotinib, an approved JAK1/2 inhibitor for myelofibrosis, was identified as a novel direct G3BP2 binder. Biotin-conjugated momelotinib pull-down assays verified specific physical interaction with recombinant G3BP2-NTF2L. Fluorescence differential scanning fluorimetry (FL-DSF) assays further confirmed target engagement, with momelotinib increasing the thermal stability of G3BP2-NTF2L at a dissociation constant (Kd) of 2.46 ± 0.75 μM. In AML cells, momelotinib selectively downregulated endogenous G3BP1/2 protein expression, thereby impairing SG formation, which verified its specific on-target G3BP-suppressive activity.
Genetic dual knockout of G3BP1 and G3BP2 in MOLM-13 AML cells drastically enhanced sensitivity to venetoclax: the IC50 of venetoclax decreased from 56 nM to 4 nM, and apoptotic cell proportion rose from 9% to 60% following 20 nM venetoclax treatment, establishing G3BP1/2 as critical mediators of venetoclax resistance. Consistent with these findings, combined treatment with momelotinib and venetoclax induced robust synergistic apoptosis and significantly reduced cell viability compared with single-agent treatment across multiple AML cell lines and primary patient-derived AML blasts. Notably, G3BP1/2 were significantly overexpressed in primary AML cells relative to healthy donor cells. Of note, momelotinib only mildly suppressed viability and even reduced venetoclax-mediated apoptosis in normal leukocytes, indicating a favorable safety profile of this combinatorial strategy for AML treatment.
Mechanistically, we characterized a previously unrecognized G3BP2-MCL1 stability axis governing venetoclax resistance in AML. G3BP2 knockdown shortened MCL1 protein half-life, whereas G3BP2 overexpression stabilized MCL1 by inhibiting its ubiquitination. Momelotinib phenocopied G3BP2 deficiency, potently promoting MCL1 proteasomal degradation via enhanced ubiquitination and shortened protein half-life. Rescue experiments with proteasome inhibitor treatment fully restored MCL1 protein levels, validating proteasome-dependent turnover as the key downstream mechanism. Furthermore, momelotinib exhibited superior synergistic pro-apoptotic effects compared with the reported G3BP2 inhibitor C108. Importantly, knockdown of JAK2 or treatment with other JAK1/2 inhibitors failed to recapitulate the synergistic efficacy, supporting that the anti-leukemic synergy is driven by G3BP inhibition rather than JAK pathway blockade.
We next assessed in vivo therapeutic efficacy of the combination in MOLM-13 NCG xenograft models. Dual-agent therapy significantly prolonged median survival from 24 days (vehicle control) to 31 days (P=0.0022). Serial bioluminescence imaging and immunohistochemical staining demonstrated profound reduction of systemic leukemic burden in combination-treated mice, whereas single-agent momelotinib or venetoclax produced only modest anti-leukemic activity.
In summary, this work identifies momelotinib as the first repurposed clinical-grade G3BP1/2 inhibitor capable of depleting G3BP proteins, suppressing SG assembly, and mitigating MCL1-mediated venetoclax resistance. The potent synergistic anti-leukemic activity of the momelotinib–venetoclax combination in primary patient samples and xenograft models provides a translatable therapeutic strategy to overcome venetoclax resistance in relapsed/refractory AML.
DISCLOSURES
Lin Xu, PhD: No relevant conflicts of interest to declare.